In the Race to Combat Climate Change, C.H. Robinson Sees 654% Increase in Renewables Business While the Booming Clean Energy Sector Faces Five Key Logistics Challenges
24.6.2021 14:00:00 EEST | Business Wire | Press release
At a time when world leaders are setting aggressive goals to fight climate change, global logistics company C.H. Robinson is realizing triple-digit growth in its renewable-energy logistics business and helping the renewables industry cope with five key challenges. Feeding the demand for wind and solar power depends not only on overcoming today’s global supply-chain disruptions, but also reducing the risks, damages, complexities and costs inherent to projects that stretch into some of the most remote places on Earth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005350/en/
C.H. Robinson helps renewable-energy companies manage the supply chain and logistics for complex projects in some of the most remote places on Earth. (Photo: Business Wire)
C.H. Robinson, which manages renewable-energy transportation and logistics from manufacturing to installation to recycling, has seen its renewables business soar 654% globally in just the past three years. This work will create 14,000 megawatts of energy – enough solar energy to charge 1.73 million electric cars and enough wind energy to power a city the size of London for four months.
Growth in renewables is being fueled by the 194 nations of the Paris climate accord pledging to reduce greenhouse gases, tech advances lowering the cost of renewables compared to fossil fuels, and utilities and the business community investing more in clean energy sources. Tax incentives in the United States have also attracted new investors. The recent extension of those tax credits and the Biden administration proposing $2 trillion in climate-related spending are likely to propel the U.S. market for the next few years. Globally, investment in the sector is expected to grow sevenfold, reaching $2.15 trillion in 2025.
“The stakes are too high for these complex projects not to succeed,” said Mike Short, C.H. Robinson’s President of Global Forwarding. “The gap between sustainability goals and enough renewable energy to meet those goals can only be filled with a viable supply chain. That supply chain stretches across continents, from mines to manufacturing plants to some of the most remote places on Earth. Wind farms are being built in the ocean. Solar farms with millions of panels are rising in the desert. Just to make a solar panel, roughly 40 different components need to get to the factory, including precious metals. These projects are built on tight timelines and budgets, and companies risk millions in unexpected costs if there are delays anywhere along the way.”
Five supply-chain barriers pose the biggest threats to keeping up with the world’s demand for green energy:
- Special equipment needs: Wind turbines keep getting bigger, with some as tall as an 85-story building. The sweep of the blades is more than an acre. Moving oversized parts requires both special expertise and equipment, including flatbed trucks that are in exceptionally short supply. This year has seen load-to-truck ratios over 100:1, meaning 100 loads waiting to be delivered for every flatbed truck available. Solar equipment, on the other hand, has sensitive electronics and glass easily subject to damage, and is also competing for transportation capacity amid one of the tightest markets in history.
- Unpredictability: Five years ago, the movement of goods such as solar panels out of Asia was high volume, low cost. Now, ship capacity is scarce and more expensive because of fewer shipping lines and a global container shortage. Port congestion makes it harder to know when your vessel will arrive, when freight will be unloaded or when enough truck chassis will be available to move it.
- Global supply chain visibility: If 45 containers a day need to arrive at a project site from different origins, knowing each load’s location at any time is critical for contingency planning, timeline management, cost mitigation, and decision-making such as whether 25 or 75 workers are needed at an installation site on any given day. Without centralized visibility and management, blind spots fuel more unpredictability and projects become subject to disparate processes across multiple vendors.
- Tighter budgets: Rising costs– from polysilicon used in solar panels to aluminum to freight charges – are adding pressure to the profitability of projects. Unexpected costs when projects don’t go as planned, like parts arriving late or damaged, can then erase profit margins. Fines are a constant threat.
- Strict timelines: Because developers and investors are hurrying to get projects started in order to meet the deadlines for tax credits, they build in contract penalties that can add up to six or seven figures for parts or equipment delivered late. Also, the nature of these vast, one-time projects makes them vulnerable to lack of resources and infrastructure to meet their needs quickly enough, especially in remote areas.
Renewable-energy companies and investors rely on C.H. Robinson not just to manage transportation, but also to provide the planning, project management, customs expertise, warehousing and on-site logistics to get clean energy projects off the ground.
“NextEnergy Capital has built, owns and operates more than 1.5 gigawatts of solar electric power plants across the world,” said Filinto Martin, Managing Director of NPIII, a NextEnergy Capital fund. “We recently had nearly 200 containers of solar panels arriving to the East Coast of the United States from Asia, with the equipment destined for two different sites. We entrusted C.H. Robinson to find local warehousing and track the inventory until the project sites were ready.”
C.H. Robinson has also helped
- A renewable-energy developer get 2,000 acres of solar panels delivered on time and on budget for a global beverage company to fulfill a sustainability pledge
- A manufacturer lower its damaged shipments to 1% and raise on-time delivery to 99%
- A manufacturer avoid penalties of up to $10,000 per load per day
“These companies cannot afford any black holes in the process, especially during one of the most volatile markets in history,” said C.H. Robinson renewables expert Jim Mancini, the vice president who oversees the company's services and technology for the energy sector. “That’s why we work to anticipate every contingency and offer visibility through our single, global multimodal technology platform, Navisphere. To keep these complex projects on track, it’s crucial to ensure that parts are where they need to be, the right transportation and specialized equipment are available, and the finished product arrives to the project site when on-the-ground teams are ready to receive and install. We are proud to leverage our scale and global suite of services to help renewable-energy companies protect and preserve our planet.”
About C.H. Robinson
C.H. Robinson solves logistics problems for companies across the globe and across industries, from the simple to the most complex. With $21 billion in freight under management and 19 million shipments annually, we are one of the world’s largest logistics platforms. Our global suite of services accelerates trade to seamlessly deliver the products and goods that drive the world’s economy. With the combination of our multi-modal transportation management system and expertise, we use our information advantage to deliver smarter solutions for our more than 105,000 customers and 73,000 contract carriers. Our technology is built by and for supply chain experts to bring faster, more meaningful improvements to our customers’ businesses. As a responsible global citizen, we are also proud to contribute millions of dollars to support causes that matter to our company, our Foundation and our employees. For more information, visit chrobinson.com (Nasdaq: CHRW).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005350/en/
Contact information
Kelsey Soby, kelsey.soby@chrobinson.com
Kaelan Richards, krichards@bpimedia.com, 617-777-3883
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
